Pharmaceuticals containing substituted piperidine compounds
Patent Information
- Application Number
- JP2023003223
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-01-14
- Filing Date
- 2023-01-12
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2043-01-12
AI Technical Summary
【0010】 本発明に係る式(I)、(II)、(III)及び(IV)で表される置換ピペリジン化合物(以下、化合物(I)、(II)、(III)及び(IV)という。)又はその薬剤学的に許容される塩は、下記の薬理試験例における活性データにて示されているようにオレキシン2型受容体作動活性を有している。本発明の化合物(I)、(II)、(III)及び(IV)は、オレキシン2型受容体作動活性を有しており、ナルコレプシーの治療剤としての利用可能性を有している。
Smart Images

Figure 0007591592000065 
Figure 0007591592000066 
Figure 0007591592000067
Abstract
Description
[Technical field]
[0001] The present invention relates to a medicine comprising, as an active ingredient, a substituted piperidine compound or a pharma- ceutically acceptable salt thereof, which has orexin type 2 receptor agonist activity. [Background technology]
[0002] Two types of brain neuropeptides, orexin-A (OX-A) and orexin-B (OX-B), which are specifically produced in certain neurons localized in the lateral hypothalamus, were discovered as endogenous ligands of the orexin receptor (Patent Documents 1-4), a G protein-coupled receptor that exists mainly in the brain (Patent Document 5, Non-Patent Document 1). There are two subtypes of orexin receptors: the type 1 subtype OX-A and the type 2 subtype OX-B. 1 Receptor (hereinafter, also referred to as OX1R) and OX2 subtype 2 It is known that orexin has a receptor (hereinafter, also referred to as OX2R). It has been found that orexin enhances feeding behavior in rats (Non-Patent Document 1).
[0003] On the other hand, gene mutations in OX2R have been reported as a cause of canine narcolepsy (Non-Patent Document 2), and orexin-deficient mice showed narcolepsy-like symptoms very similar to those of human or canine narcolepsy (Non-Patent Document 3). Furthermore, a study using a transgenic mouse with degenerated orexin neurons and a double transgenic mouse obtained by crossing this mouse with an orexin-overexpressing transgenic mouse revealed that the narcolepsy-like symptoms caused by the degeneration of orexin neurons disappeared with the sustained expression of orexin (Non-Patent Document 4). Similarly, when OX-A was administered intracerebroventricularly to a transgenic mouse with degenerated orexin neurons, the narcolepsy-like symptoms, such as suppression of cataplexy-like behavioral arrest and increased wakefulness, were improved (Non-Patent Document 4). Furthermore, a study of OX2R knockout mice suggests that OX2R is important for maintaining wakefulness (Non-Patent Document 5). It has also been suggested that daytime sleepiness in Parkinson's disease patients is caused by the loss of orexin neurons (Non-Patent Document 6). In addition, it has been suggested that patients with sleep apnea syndrome have low plasma OX-A concentration levels (Non-Patent Document 7). In light of this background, it has been suggested that OX2R agonists could be used as therapeutic agents for narcolepsy and other sleep disorders that involve hypersomnia (Non-Patent Document 8).
[0004] Therefore, compounds having OX2R agonist activity are considered to be useful as therapeutic agents for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, disorders of consciousness such as coma, narcolepsy syndrome accompanied by narcolepsy-like symptoms, and hypersomnia syndrome accompanied by excessive daytime sleepiness (e.g., Parkinson's disease, Guillain-Barré syndrome, and Kleine-Levin syndrome).
[0005] TAK-925, a compound with OX2R agonist activity, is currently undergoing phase 1 clinical trials (intravenous administration) in healthy subjects and patients with narcolepsy. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] WO1996 / 34877 [Patent Document 2] Japanese Unexamined Patent Application Publication No. 10-327888 [Patent Document 3] Japanese Unexamined Patent Application Publication No. 10-327889 [Patent Document 4] Japanese Unexamined Patent Application Publication No. 11-178588 [Patent Document 5] Japanese Unexamined Patent Application Publication No. 10-229887 [Non-Patent Document]
[0007] [Non-Patent Document 1] Sakurai T.et al,Cell,1998,92,573-585 [Non-Patent Document 2] Lin L. et al,Cell,1999,98,365-376 [Non-Patent Document 3] Chemelli R.M.et al,Cell,1999,98,437-451 [Non-Patent Document 4] Mieda M.et al,Proc.Natl.Acad.Sci.USA,2004,101,4649-4654 [Non-Patent Document 5] Willie J.T. et al,Neuron,2003,38,715-730 [Non-Patent Document 6] Thannickal T.C.et al,Brain.2007,130,1586-1595 [Non-Patent Document 7] Busquets X.et al,Respiration,2004,71,575-579 [Non-Patent Document 8] Mieda M.et al,CNS Drugs,2013,27,83-90 [Summary of the Invention] [Problems to be Solved by the Invention]
[0008] An object of the present invention is to provide a medicine containing a substituted piperidine compound or a pharma- ceutically acceptable salt thereof having orexin type 2 receptor agonist activity. [Means for solving the problem]
[0009] That is, the present invention relates to the following [1] to
[17] . [1] The following formula (I) [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula A medicine comprising a compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof. [2] The following formula (I) [ka] or a pharma- ceutical agent comprising a 2R-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula: [3] The following formula (II) [ka] A medicine comprising (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula: [4] The following formula (III) [ka] A medicine comprising (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula: [5] The following formula (IV) [ka] or a pharma- ceutical agent comprising a 2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula: [6] The following formula (I): [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula A pharmaceutical composition comprising a compound selected from the group consisting of: [7] The pharmaceutical agent according to any one of [1] to [5] above, which is an orexin type 2 receptor agonist. [8] The pharmaceutical agent according to any one of [1] to [5] above, which is a therapeutic agent for narcolepsy. [9] For producing a pharmaceutical composition for treating narcolepsy, The following formula (I) [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula Use of a compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
[10] The pharmaceutical agent according to any one of [1] to [5] above, which is a therapeutic agent for cataplexy.
[11] For the preparation of a pharmaceutical composition for the treatment of cataplexy, The following formula (I) [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula Use of a compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
[12] The pharmaceutical agent according to any one of [1] to [5] above, which is a therapeutic agent for hypersomnia syndrome.
[13] For the preparation of a pharmaceutical composition for the treatment of hypersomnia syndrome, The following formula (I) [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula Use of a compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
[14] The following formula (I) [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula 13. An orexin type 2 receptor agonist comprising a compound selected from the group consisting of:
[15] The following formula (I) [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula A therapeutic agent for narcolepsy, comprising a compound selected from the group consisting of:
[16] The following formula (I) [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula A therapeutic agent for cataplexy, comprising a compound selected from the group consisting of:
[17] The following formula (I) [ka] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III) [ka] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV) [ka] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula A therapeutic agent for hypersomnia syndrome, comprising a compound selected from the group consisting of: Effect of the Invention
[0010] The substituted piperidine compounds represented by formulas (I), (II), (III) and (IV) according to the present invention (hereinafter referred to as compounds (I), (II), (III) and (IV)) or pharma- ceutical acceptable salts thereof have orexin type 2 receptor agonist activity as shown by the activity data in the following pharmacological test examples. Compounds (I), (II), (III) and (IV) according to the present invention have orexin type 2 receptor agonist activity and are usable as therapeutic agents for narcolepsy. [Brief description of the drawings]
[0011] [Figure 1] FIG. 1 is an ORTEP diagram showing the results of X-ray crystal structure analysis of the compound obtained in Example 1. [Diagram 2] FIG. 2 is an ORTEP diagram showing the results of X-ray crystal structure analysis of the compound obtained in Example 3 (a dimer having two molecules of acetonitrile added). [Diagram 3] FIG. 3 is an ORTEP diagram showing the results of X-ray crystal structure analysis of the compound obtained in Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The present invention will be described in detail below.
[0013] The compounds according to the present invention may exist in the form of crystalline polymorphs, but are not limited thereto, and may be a single crystal form or a mixture of crystal forms. The compounds according to the present invention also include amorphous forms, and include anhydrates and solvates (particularly hydrates).
[0014] The present invention also includes isotopically labeled compounds of compounds (I), (II), (III) and (IV). Isotopically labeled compounds are identical to compounds (I), (II), (III) and (IV) except that one or more atoms have been replaced with an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Isotopes that can be incorporated into the compounds of the present invention include, for example, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, phosphorus, sulfur, iodine and chlorine. 2 H, 3 H, 11 C. 14 C. 15 N, 18 O. 18 F, 32 P, 35 S, 123 I, and 125 I and others are included.
[0015] The isotopically labeled compound, for example, 3 H and / or 14 Compounds incorporating radioactive isotopes such as C are useful in drug and / or substrate tissue distribution assays. 3 H and 14 C are considered useful because of their ease of preparation and detection. 11 C and 18 F is considered useful in PET (positron emission tomography) and is an isotope 125I is considered useful in SPECT (single photon emission computed tomography), all of which are useful in brain imaging. 2 Substitution with heavier isotopes such as H may confer certain therapeutic advantages, such as increased in vivo half-life or reduced dosage requirements due to greater metabolic stability, and therefore may be considered useful in certain circumstances. The above isotopically labeled compounds can be uniformly prepared by following the procedures disclosed in the Examples below, substituting readily available isotopically labeled reagents for non-isotopically labeled reagents.
[0016] The term "pharmaceutical acceptable salt" as used herein is not particularly limited as long as it is a salt that can be formed with the compound of the present invention, and specific examples thereof include acid addition salts such as inorganic acid salts, organic acid salts, and acidic amino acid salts.
[0017] In this specification, unless otherwise specified, the term "pharmaceutical acceptable salt" refers to a salt formed in an appropriate ratio, and in the formed salt, the number of molecules of acid per molecule of the compound is not particularly limited, but preferably is about 0.5 to about 2 molecules of acid per molecule of the compound, and more preferably is about 0.5, about 1, or about 2 molecules of acid per molecule of the compound.
[0018] Preferred examples of inorganic acid salts include hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates, and preferred examples of organic acid salts include acetates, succinates, fumarates, maleates, tartrates, citrates, lactates, stearates, benzoates, methanesulfonates, p-toluenesulfonates, and benzenesulfonates.
[0019] Preferred examples of acidic amino acid salts include aspartates and glutamates.
[0020] When the compounds (I), (II), (III) and (IV) according to the present invention are obtained as free forms, they can be converted into salts which the compounds (I), (II), (III) and (IV) may form or into hydrates thereof in a conventional manner.
[0021] When the compounds (I), (II), (III) and (IV) according to the present invention are obtained as salts of the compounds (I), (II), (III) and (IV) or hydrates of the compounds (I), (II), (III) and (IV), they can be converted into the free forms of the compounds (I), (II), (III) and (IV) according to a conventional method.
[0022] Furthermore, various isomers (e.g., optical isomers, rotational isomers, stereoisomers, etc.) obtained with respect to the compounds (I), (II), (III) and (IV) according to the present invention can be purified and isolated by using a conventional separation means, for example, recrystallization, a diastereomeric salt method, an enzymatic resolution method, various types of chromatography (e.g., thin layer chromatography, column chromatography, gas chromatography, etc.).
[0023] [formulation] The pharmaceutical composition according to the present invention can be produced by mixing a pharma- ceutical acceptable additive with a compound selected from the compound groups (I), (II), (III) and (IV) or a pharma- ceutical acceptable salt thereof. The pharmaceutical composition according to the present invention can be produced according to a known method, for example, the method described in the General Provisions for Preparations in the Seventeenth Edition of the Japanese Pharmacopoeia.
[0024] The pharmaceutical composition according to the present invention can be administered to a patient appropriately depending on its dosage form.
[0025] The dosage of the compounds (I), (II), (III) and (IV) according to the present invention, or pharma- ceutically acceptable salts thereof, will vary depending on the severity of symptoms, age, sex, body weight, dosage form, type of salt, specific type of disease, etc., but for adults, the dosage is usually about 30 μg to 10 g, preferably 100 μg to 5 g, more preferably 100 μg to 1 g per day by oral administration, or about 30 μg to 1 g, preferably 100 μg to 500 mg, more preferably 100 μg to 300 mg by injection, administered once or in divided doses.
[0026] As used herein, the term "orexin type 2 receptor agonist" refers to a drug that binds to the orexin type 2 receptor and has the effect of activating the orexin type 2 receptor in the same manner as an endogenous ligand.
[0027] The compound of the present invention can be used as a chemical probe for capturing a target protein of a physiologically active low molecular weight compound. That is, the compound of the present invention can be converted into an affinity chromatography or photoaffinity probe by introducing a labeling group, a linker, or the like to a portion different from the structural portion essential for the activity of the compound by the method described in J. Mass Spectrum. Soc. Jpn. Vol. 51, No. 5, 2003, p. 492-498 or WO2007 / 139149, etc.
[0028] Examples of the labeling group, linker, etc. used in the chemical probe include groups shown in the group consisting of (1) to (5) below. (1) Protein labeling groups such as photoaffinity labeling groups (e.g., benzoyl groups, benzophenone groups, azide groups, carbonylazide groups, diaziridine groups, enone groups, diazo groups, and nitro groups) and chemical affinity groups (e.g., ketone groups in which the alpha carbon atom is substituted with a halogen atom, carbamoyl groups, ester groups, alkylthio groups, α,β-unsaturated ketones, Michael acceptors such as esters, and oxirane groups), (2) Cleavable linkers such as -SS-, -O-Si-O-, monosaccharides (glucose groups, galactose groups, etc.) or disaccharides (lactose, etc.), and oligopeptide linkers that can be cleaved by an enzyme reaction; (3) fishing tag groups such as biotin and 3-(4,4-difluoro-5,7-dimethyl-4H-3a,4a-diaza-4-bora-s-indacen-3-yl)propionyl groups; (4) 125 I, 32 P, 3 H, 14 radioactive labeling groups such as C; fluorescent labeling groups such as fluorescein, rhodamine, dansyl, umbelliferone, 7-nitrofurazanyl, 3-(4,4-difluoro-5,7-dimethyl-4H-3a,4a-diaza-4-bora-s-indacen-3-yl)propionyl groups; chemiluminescent groups such as lumiferin and luminol; detectable markers such as lanthanide metal ions, radium ions, and other heavy metal ions; (5) Groups for binding to solid phase supports such as glass beads, glass beds, microtiter plates, agarose beads, agarose beds, polystyrene beads, polystyrene beds, nylon beads, nylon beds, etc.
[0029] A probe prepared by introducing a labeling group selected from the group consisting of (1) to (5) into the compound of the present invention in accordance with the method described in the above document can be used as a chemical probe for identifying a labeled protein, which is useful for searching for new drug discovery targets, etc. EXAMPLES
[0030] Compounds (I), (II), (III) and (IV) of the present invention can be prepared, for example, by the methods described in the following Examples, and the effects of the compounds can be confirmed by the methods described in the following Test Examples. However, these are merely illustrative, and the present invention is not limited to the following specific examples in any case, and may be modified within the scope of the present invention.
[0031] Compounds with reference names or the like described therein were prepared in accordance with the references or the like.
[0032] The abbreviations used in this specification are conventional abbreviations well known to those skilled in the art. n-:Normal tert-: tertiary 1 H-NMR: Proton nuclear magnetic resonance spectrometry MS: Mass spectrometry HPLC: High-performance liquid chromatography
[0033] In the following Examples and Preparation Examples, "room temperature" generally refers to about 10° C. to about 35° C. Unless otherwise specified, % refers to percent by weight.
[0034] Chemical shifts in proton nuclear magnetic resonance spectra are reported in δ units (ppm) relative to tetramethylsilane, coupling constants are reported in Hertz (Hz), and patterns are designated, for example, s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet, br: broad, brs: broad singlet, etc.
[0035] Mass spectrometry was performed using Waters Acquity UPLC (registered trademark) or Acquity UPC 2 (registered trademark).
[0036] For chromatography, silica gel used was Merck's Silica Gel 60 (70-230 mesh or 230-400 mesh ASTM) or Fuji Silysia Chemical's PSQ60B, or a prepacked column {column: Yamazen's Hi-Flash TM Column (Silicagel), size: S (16 x 60 mm), M (20 x 75 mm), L (26 x 100 mm), 2L (26 x 150 mm), 3L (46 x 130 mm), or Biotage TMSNAP Ultra Silica Cartridge, size: 10 g, 25 g, or 50 g} was used. Separation by supercritical fluid chromatography (SFC) was performed using Prep100q manufactured by Waters.
[0037] NH silica gel is CHROMATOREX NH-DM2035 manufactured by Fuji Silysia Chemical Co., Ltd., or a prepacked column (column: Hi-Flash manufactured by Yamazen Co., Ltd.) is used. TM (registered trademark) Column (Amino), size: S (16 x 60 mm), M (20 x 75 mm), L (26 x 100 mm), 2L (26 x 150 mm), 3L (46 x 130 mm), or Presep (manufactured by Wako Pure Chemical Industries, Ltd.) TM (registered trademark) (Luer Lock) NH2 (HC), size: Type M (14 g / 25 mL), Type L (34 g / 70 mL), Type 2L (50 g / 100 mL), or Type 3L (110 g / 200 mL) was used.
[0038] The names of the compounds shown below are those displayed in "E-Notebook" version 12 or 13 (PerkinElmer Co.), except for commonly used reagents.
[0039] Manufacturing Example 1 Synthesis of 2-bromo-2-cyclopropylacetamide [ka] Oxalyl chloride (CAS No. 79-37-8) (3.11 mL, 36.3 mmol) and N,N-dimethylformamide (60.0 μL, 0.775 mmol) were added to a solution of cyclopropylacetic acid (CAS No. 5239-82-7) (3.30 g, 33.0 mmol) in 1,2-dichloroethane (60 mL), and the mixture was stirred at room temperature for 40 minutes. Hydrobromic acid (56.0 mg, 0.330 mmol) and N-bromosuccinimide (CAS No. 128-08-5) (7.04 g, 39.6 mmol) were added to the reaction solution, and the mixture was heated to reflux for 18 hours. The reaction solution was added to ammonia (28% aqueous solution, 60 mL, 2.77 mol) at 0°C, and ethyl acetate and sodium hydroxide (2N aqueous solution) were added to separate the mixture. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting solid was triturated with ethyl acetate / n-heptane, and the precipitate was collected by filtration and dried under reduced pressure to give the title compound (1.20 g). MS(ESI)m / z:178[M+H] +
[0040] Manufacturing Example 2 Synthesis of 3-methoxyisonicotinonitrile [ka] Sodium methoxide (CAS No. 124-41-4) (3.90 g, 72.2 mmol) was added to a solution of 3-chloro-4-cyanopyridine (CAS No. 68325-15-5) (5.00 g, 36.1 mmol) in tetrahydrofuran (36.0 mL) at room temperature, and the mixture was heated to reflux for 1 hour. Water and ethyl acetate were added to the reaction mixture, and the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained solid was triturated with ethyl acetate / n-heptane, and the precipitate was collected by filtration. The obtained solid was dried under reduced pressure to obtain the title compound (1.91 g). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):4.06(s,3H),7.44(d,J=5.0Hz,1H),8.37(d,J=4.5Hz,1H),8.49(s,1H). MS(ESI)m / z:135[M+H] +
[0041] Production Example 3 Synthesis of (R)-2-bromo-3-methylbutanamide [ka] Oxalyl chloride (9.28mL, 108mmol) and N,N-dimethylformamide (30.0μL, 0.387mmol) were added to a solution of (R)-2-bromo-3-methylbutyric acid (CAS No. 76792-22-8) (9.80g, 54.1mmol) in methylene chloride (100mL) at 0℃, and the mixture was stirred at room temperature for 6 hours. The reaction solution was added to ammonia (28% aqueous solution, 50.0mL, 2.31mol) at 0℃, and extracted with methylene chloride. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained solid was triturated with ethyl acetate / n-heptane, and the precipitate was collected by filtration. The obtained solid was dried under reduced pressure to obtain the title compound (8.20g). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.01(d,J=6.3Hz,3H),1.07(d,J=6.8Hz,3H),2.34-2.39(m,1H),4.28(d,J=4.5Hz,1H),5.58(brs,1H),6.41(brs,1H). MS(ESI)m / z:180[M+H] +
[0042] Production Example 4 Synthesis of (1R,3s,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane [ka]
[0043] (1) Synthesis of tert-butyl (1R,3r,5S)-3-hydroxy-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate 3-Methoxyisonicotinonitrile (1.19g, 8.88mmol) and bis(pinacolato)diboron (CAS No.73183-34-3) (2.25g, 8.88mmol) were added to a solution of N-(tert-butoxycarbonyl)-nortropinone (CAS No.185099-67-6) (1.00g, 4.44mmol) in methyl tert-butyl ether (18.0mL), and the mixture was heated to reflux for 16 hours. Sodium carbonate (2mol / L aqueous solution, 20.0mL) was added to the reaction mixture at 0℃, and the mixture was stirred at 0℃ for 20 minutes. Ethyl acetate was added to the reaction mixture, and the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0-20% methanol / ethyl acetate) to obtain the title compound (1.12g). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.48(s,9H),1.77(m,2H),1.94-1.99(m,2H),2.21-2.32(m,2H),2.37-2.48(m,1H),2.63-2.74(m,1 H),2.78(s,1H),3.96(s,3H),4.22-4.29(m,1H),4.31-4.42(m,1H),7.28(d,J=5.4Hz,1H),8.22-8.25(m,2H). MS(ESI)m / z:335[M+H] +
[0044] (2) Synthesis of tert-butyl (1R,5S)-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate tert-Butyl (1R,3r,5S)-3-hydroxy-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (610 mg, 1.82 mmol) was added with concentrated sulfuric acid (1.60 mL, 30.0 mmol) and stirred at room temperature for 40 minutes. The reaction mixture was added to a solution of potassium hydroxide (5.00 g, 89.1 mmol) in water (10.0 mL) at 0°C. Tetrahydrofuran (10.0 mL) and di-tert-butyl dicarbonate (CAS No. 24424-99-5) (478 mg, 2.19 mmol) were added to the reaction mixture and stirred at room temperature for 10 minutes. Ethyl acetate was added to the reaction mixture and the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5-100% ethyl acetate / n-heptane) to obtain the title compound (420 mg). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.46(s,9H),1.72-1.81(m,1H),1.97-2.03(m,2H),2.05-2.36(m,2H),2.94-3.26(m,1H),3.8 7(s,3H),4.21-4.61(m,2H),6.30(brs,1H),6.99(d,J=4.5Hz,1H),8.17(d,J=5.0Hz,1H),8.21(s,1H). MS(ESI)m / z:317[M+H] +
[0045] (3) Synthesis of tert-butyl (1R,5S)-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate 10% palladium carbon (Kawaken Fine Chemicals Co., Ltd., AD, 52.7% water content, 284 mg, 0.126 mmol) was added to a solution of tert-butyl (1R,5S)-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (400 mg, 1.26 mmol) in methanol (3.00 mL), and the mixture was stirred at room temperature under a hydrogen atmosphere for 1 hour. The reaction solution was filtered through Celite (registered trademark), and the residue was washed with ethyl acetate. The filtrate obtained was concentrated under reduced pressure to give a mixture of endo and exo isomers (endo:exo=1:2, 398 mg). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.49(s,6H),1.50(s,3H),1.61-2.13(m,22 / 3H),2.40-2.45(m,2 / 3H),2.96-3.01(m,1 / 3H),3.47-3.59(m,2 / 3H),3.8 8(s,1H),3.90(s,2H),4.16-4.28(m,1H),4.34(brs,1H),7.04(d,J=4.5Hz,2 / 3H),7.06(d,J=5.0Hz,1 / 3H),8.13-8.23(m,2H). MS(ESI)m / z:319[M+H] +
[0046] (4) Synthesis of tert-butyl (1R,3s,5S)-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate Potassium tert-butoxide (281 mg, 2.50 mmol) was added to a solution of tert-butyl (1R,5S)-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (398 mg, 1.25 mmol) in tert-butanol (4.00 mL), and the mixture was heated under reflux for 17 hours. Ethyl acetate and saturated saline were added to the reaction mixture, and the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (385 mg). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.49(s,9H),1.58-2.06(m,8H),3.49-3.56(m,1H),3.90(s,3H) ,4.24(brs,1H),4.34(brs,1H),7.04(d,J=5.0Hz,1H),8.17-8.19(m,2H). MS(ESI)m / z:319[M+H] +
[0047] (5) Synthesis of tert-butyl (1R,3s,5S)-3-(1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate 10% palladium carbon (Kawaken Fine Chemicals Co., Ltd., AD, 52.7% water content, 7.91 g, 3.52 mmol) was added to a solution of tert-butyl (1R,3s,5S)-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (11.2 g, 35.2 mmol) in acetic acid (100 mL), and the mixture was stirred at 70° C. for 18 hours under a hydrogen atmosphere. The reaction solution was filtered through Celite®, and the residue was washed with ethyl acetate. The obtained filtrate was concentrated under reduced pressure. Ethyl acetate and sodium hydroxide (2N) were added to the residue, and the organic layer was separated. The organic layer was dried over ISOLUTE® HM-N, filtered, and concentrated under reduced pressure. To the residue, N,N-dimethylformamide (50.0 mL), 2-chloro-5-fluoropyrimidine (CAS No. 62802-42-0) (5.21 mL, 42.2 mmol) and potassium carbonate (7.29 g, 52.8 mmol) were added and stirred at 80°C for 40 minutes. Ethyl acetate and saturated saline were added to the reaction mixture, and the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10-60% ethyl acetate / n-heptane) to obtain the title compound (9.84 g). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.19-1.30(m,3H),1.46(s,9H),1.46-1.65(m,6H),1.81-1.97(m,3H),2.68(d,J=14.5Hz,1H),2.71-2 .81(m,1H),3.30(s,3H),3.35(brs,1H),4.08-4.31(m,2H),4.64-4.77(m,1H),5.04-5.18(m,1H),8.13(s,2H). MS(ESI)m / z:421[M+H] +
[0048] (6) Synthesis of tert-butyl (1R,3s,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate Tert-butyl (1R,3s,5S)-3-(1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (7.00 g, 16.6 mmol) was separated in 100 mg portions per run using a Daicel CHIRALPAK (registered trademark) IC / SFC (3 cm x 25 cm) (mobile phase CO2:methanol (90:10), 120 bar, 40°C, flow rate: 100 mL / min), and the title compound (3.02 g) was obtained with a retention time of 8.45 min. 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.17-1.29(m,3H),1.46(s,9H),1.46-1.66(m,6H),1.85-1.97(m,3H),2.68(d,J=15.0Hz,1H),2.75(td,J=12.9, 3.2Hz,1H),3.30(s,3H),3.35(brs,1H),4.11-4.31(m,2H),4.66-4.76(m,1H),5.10(dt,J=14.4,2.6Hz,1H),8.13(s,2H). MS(ESI)m / z:443[M+Na] + (Analysis conditions) Supercritical fluid chromatography using Daicel CHIRALPAK (registered trademark) IC-3 (3.0 mm x 50 mm) (mobile phase CO2:methanol (85:15), 40°C, flow rate: 1.2 mL / min, detection: UV (254 nm)) (Analysis results) The retention time of the title compound was 1.34 minutes, and the optical purity was >99% ee.
[0049] (7) Synthesis of (1R,3s,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane Trifluoroacetic acid (5.00 mL, 64.9 mmol) was added to tert-butyl (1R,3s,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (1.00 g, 2.38 mmol) and stirred at room temperature for 20 minutes. The reaction solution was concentrated under reduced pressure. 2N aqueous sodium hydroxide solution was added to the residue, and the mixture was extracted with ethyl acetate (three times). The combined organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (620 mg). MS(ESI)m / z:321[M+H] +
[0050] Production Example 5 Synthesis of (S)-2-bromo-2-cyclopropylacetamide [ka]
[0051] (1) Synthesis of (S)-3-(2-cyclopropylacetyl)-4-phenyloxazolidin-2-one Pivaloyl chloride (302 mL, 2470 mmol) was added to tetrahydrofuran (7000 mL) at room temperature. Cyclopropylacetic acid (238 mL, 2450 mmol) was added to the mixture at room temperature and cooled to 0°C. Triethylamine (350 mL) was added dropwise over 10 minutes, and then triethylamine (400 mL, total amount 5340 mmol) was added and stirred at 0°C for 76 minutes. (S)-4-phenyloxazolidin-2-one (350 g, 2140 mmol) was added to the reaction mixture in one portion, and then lithium chloride (109 g, 2570 mmol) was added in one portion. The reaction mixture was stirred at room temperature for 18 hours, and then ethyl acetate (7000 mL) and water (3500 mL) were added and stirred at room temperature for 40 minutes. The organic layer was separated and washed successively with 5% aqueous sodium bicarbonate solution (3500 mL) and water (1750 mL). The obtained organic layer was concentrated to 1750 mL. Ethyl acetate (2100 mL) was added and the azeotropic operation of concentrating to 1750 mL was repeated three times, and then ethyl acetate (1050 mL) was further added to concentrate to 1750 mL. The obtained concentrated liquid was stirred, and n-heptane (1000 mL) was added dropwise. The resulting suspension was stirred for 10 minutes, and n-heptane (2500 mL) was further added dropwise. The mixture was stirred at room temperature overnight, and then stirred at 0°C for another 3.5 hours. The resulting solid was filtered using a glass filter and washed with a mixed solution of ethyl acetate / n-heptane (1:3, 550 mL). The obtained solid was dried under reduced pressure to obtain the title compound (407 g). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):0.09-0.24(m,2H)0.46-0.58(m,2H)1.00-1.13(m,1H),2.74-2.83(m,1H),2.88-2.98(m, 1H),4.25-4.32(m,1H),4.70(t,J=8.83Hz,1H),5.45(dd,J=8.83,3.85Hz,1H),7.28-7.43(m,5H).
[0052] (2) Synthesis of (S)-2-bromo-2-cyclopropylacetamide To a solution of (S)-3-(2-cyclopropylacetyl)-4-phenyloxazolidin-2-one (100g, 408mmol) in dichloromethane (1000mL), 1M dichloromethane solution of dibutylboron triflate (500mL, 500mmol) was added dropwise over 40 minutes under ice cooling, and the mixture was stirred for 10 minutes under ice cooling. N,N-diisopropylethylamine (92mL, 530mmol) was added dropwise over 25 minutes under ice cooling, and the mixture was stirred for 1 hour under ice cooling. The reaction mixture was then cooled to an internal temperature of -72°C in a dry ice-ethanol bath. N-bromosuccinimide (80g, 448mmol) was added in one portion, and the mixture was stirred for 1 hour and 20 minutes under a dry ice-ethanol bath. 28-30% aqueous ammonia (800mL, 6390mmol) and tetrahydrofuran (1000mL) were added, and the mixture was stirred for 2 hours under a water bath. After separating the organic layer and the aqueous layer, the aqueous layer was extracted three times with ethyl acetate (500 mL). The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (silica gel 4 kg, 30-40% ethyl acetate / n-heptane) to obtain 132 g of crude product. tert-butyl methyl ether (1440 mL) was added to the crude product and stirred at 50°C for one hour to dissolve it. The mixture was stirred at room temperature for one day. The resulting solid was filtered and washed with tert-butyl methyl ether (200 mL). The filtrate and washings were combined, and ethyl acetate (700 mL) and activated carbon (purified Shirasagi, 26 g) were added thereto and stirred at room temperature for 30 minutes. The activated carbon was removed by filtration through Celite (registered trademark), and the activated carbon was washed with ethyl acetate (700 mL). The filtrate and washings were combined and then concentrated under reduced pressure to obtain the title compound (97.1 g, content 65.9%). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):0.40-0.52(m,1H),0.63-0.73(m,1H),0.77-0.86(m,1H),0.86-0.97(m, 1H),1.41-1.50(m,1H),3.59-3.83(m,1H),5.34-5.71(m,1H),5.94-6.30(m,1H). MS(ESI)m / z:180[M+H] + (Analysis conditions) Chromatography using Daicel CHIRALPAK (registered trademark) IA (0.46 cm x 25 cm x 2 tubes) (mobile phase: ethanol: n-hexane (10:90), 40°C, flow rate: 0.8 mL / min, detection: UV (210 nm)) (Analysis results) The retention time of the title compound was 24.5 minutes.
[0053] Example 1 Synthesis of (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide [ka] 2-Bromo-2-cyclopropylacetamide (433 mg, 2.43 mmol), cesium carbonate (793 mg, 2.43 mmol), and silver oxide (564 mg, 2.43 mmol) were added to a solution of (1R, 3s, 5S)-3-((3S, 4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane (260 mg, 0.811 mmol) in acetonitrile (4.00 mL), and the mixture was stirred at room temperature for 40 hours. The reaction solution was directly purified by column chromatography (silica gel, 20% methanol / ethyl acetate). The resulting product was dissolved in methanol (10 mL) and loaded onto a Waters Porapak Rxn® CX (two 2 g cartridges). After washing the solid phase with methanol (20 mL), the product was eluted with ammonia (2 mol / L methanol solution, 20 mL), and the combined eluate was concentrated under reduced pressure. The residue was dissolved in methanol and separated into 10 mg / 500 μL (methanol) portions per run using supercritical fluid chromatography (mobile phase CO2:methanol (85:15), 120 bar, 40°C, flow rate: 70 mL / min) using Daicel CHIRALPAK (registered trademark) OD-H / SFC (2 cm x 25 cm), and the compound (120 mg) with a retention time of 6.41 minutes was obtained as an enantiomer mixture. The obtained compound was dissolved in methanol, and 13 mg / 500 μL (methanol) was collected per run by supercritical fluid chromatography (mobile phase CO2:methanol (75:25), 120 bar, 40 ° C, flow rate: 70 mL / min) using Daicel CHIRALPAK (registered trademark) IG / SFC (2 cm × 25 cm), and a compound (75 mg) with a retention time of 9.11 minutes, mainly consisting of components that will be eluted later, was obtained. The obtained compound was dissolved in methanol, and 4 mg / 100 μL (methanol) was collected per run by supercritical fluid chromatography (mobile phase CO2:methanol (75:25), 120 bar, 40 ° C, flow rate: 70 mL / min) using Daicel CHIRALPAK (registered trademark) IG / SFC (2 cm × 25 cm), and a compound (52 mg) with a retention time of 7.52 minutes, mainly consisting of components that will be eluted later, was obtained.The obtained compound was dissolved in methanol and separated in 7 mg / 500 μL (methanol) portions per run using supercritical fluid chromatography (mobile phase CO2:methanol (75:25), 120 bar, 40°C, flow rate: 70 mL / min) using a Daicel CHIRALPAK (registered trademark) IG / SFC (2 cm x 25 cm), to obtain the title compound (31.3 mg) with a retention time of 7.18 min, which was eluted later. 1 H-NMR (400MHz, CDCl 3 )δ(ppm):0.28-0.37(m,1H),0.45-0.52(m,1H),0.53-0.58(m,1H),0.60-0.68(m,1H),0.78(dd,J=8.8,4.3Hz,1H),1.20 -1.27(m,2H),1.32-1.45(m,2H),1.46-1.52(m,2H),1.59-1.65(m,3H),1.70-1.80(m,2H),1.81-1.88(m,1H),2.08(d,J =9.1Hz,1H),2.68(dd,J=14.3,1.1Hz,1H),2.75(td,J=12.8,2.9Hz,1H),3.21-3.24(m,1H),3.30(s,3H),3.36(brs,1H) ,3.86-3.91(m,1H),4.65-4.76(m,1H),5.10(dt,J=14.2,2.4Hz,1H),5.14-5.24(m,1H),6.92-7.02(m,1H),8.14(s,2H). MS(ESI)m / z:418[M+H] + (Analysis conditions) Chromatography using Daicel CHIRALPAK (registered trademark) IA (0.46 cm x 15 cm) (mobile phase: ethanol: hexane (20:80), 40°C, flow rate: 1 mL / min, detection: UV (254 nm)) (Analysis results) The retention time of the title compound was 4.91 minutes, and the optical purity was >99% ee.
[0054] Preparation and X-ray crystal structure analysis of single crystals of (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide The title compound (2.97 mg) obtained in Example 1 was dissolved in methanol (1 mL). 500 μL of the solution was placed in a vial and the cap was closed loosely (solvent evaporation method). After one day, a single crystal of the title compound was obtained in the vial. X-ray crystal structure analysis was performed on the obtained single crystal under the following conditions. The X-ray crystal structure of the title compound is shown in FIG. 1. Analytical equipment: XtaLAB PROP200 MM007HF (Rigaku, Japan) Software: CrysAlisPro (Rigaku Oxford Diffraction) X-ray: multi-layer mirror monochromated Cu-Kα (40kV / 30 mA) Measurement method: ω axis oscillation method Camera length: 35 mm Measurement temperature: -170℃
[0055] The IUPAC name of (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide synthesized in Example 1 is (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide.
[0056] Example 2 Synthesis of (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide [ka] (1R,3s,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane (290 mg, 0.905 mmol) in acetonitrile (8.00 mL) was added with (R)-2-bromo-3-methylbutanamide (326 mg, 1.81 mmol), cesium carbonate (590 mg, 1.81 mmol), and silver oxide (419 mg, 1.81 mmol) and stirred at room temperature for 40 hours. The reaction solution was filtered through silica gel, and the residue was washed with 20% methanol / ethyl acetate. The obtained filtrate was concentrated under reduced pressure. The residue was dissolved in methanol (5 mL) and applied to Waters Porapak Rxn (registered trademark) CX (bulk, 4 g). After washing the solid phase with methanol (40 mL), the product was eluted with ammonia (2N methanol solution, 40 mL), and the eluate was concentrated under reduced pressure. The residue was separated in 5 mg portions per run using supercritical fluid chromatography (mobile phase CO2:methanol (80:20), 120 bar, 40°C, flow rate: 70 mL / min) using Daicel CHIRALPAK (registered trademark) IG / SFC (2 cm x 25 cm), and the title compound (154 mg) with a retention time of 4.41 minutes was obtained. 1 H-NMR (400MHz, CDCl 3 )δ(ppm):0.95(d,J=6.8Hz,3H),1.02(d,J=6.8Hz,3H),1.15-1.56(m,8H),1.75(td,J=10 .8,6.1Hz,3H),1.86-2.10(m,2H),2.67(d,J=13.1Hz,1H),2.75(td,J=12.9,3.2Hz,1H),2 .95(d,J=4.1Hz,1H),3.19-3.27(m,1H),3.30(s,3H),3.33-3.46(m,2H),4.70(dt,J=13.3 ,2.2Hz,1H),5.06-5.16(m,1H),5.30-5.36(m,1H),6.79(brd,J=5.0Hz,1H),8.14(s,2H). MS(ESI)m / z:421[M+H] +
[0057] Example 3 Synthesis of (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide [ka]
[0058] (1) Synthesis of tert-butyl (1R,3s,5S)-3-((3S,4R)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate hemi(2S,3S)-2,3-bis((4-methylbenzoyl)oxy)succinate A mixture of tert-butyl (1R,3s,5S)-3-(3-methoxypyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (20 g, 62.8 mmol) and 10% palladium carbon (Kawaken Fine Chemicals Type AD, approximately 50% water content, 6 g) in acetic acid (160 mL) was stirred overnight at 70°C under a hydrogen atmosphere. The palladium carbon was removed by filtration, washed with methanol (10 times the volume), and the filtrate was concentrated to approximately twice the volume. Isopropyl acetate (15 times the volume) and n-heptane (3 times the volume) were added to the concentrated liquid obtained, and then washed with 48% sodium hydroxide aqueous solution (54.7 mL). n-heptane (100 mL) was added, washed with water (5 times the volume), and concentrated to approximately 5 times the volume. Isopropyl acetate (5 times the amount) was added to the obtained concentrated liquid, and the azeotropic operation of concentrating the liquid to approximately 5 times the amount was repeated twice to obtain tert-butyl (1R,3s,5S)-3-(3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (15.1 g) as an isopropyl acetate solution. The obtained tert-butyl (1R,3s,5S)-3-(3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (7.55 g, 23.3 mmol) and (+)-dipivaloyl-D-tartaric acid (1.85 g, 5.82 mmol) were dissolved in isopropyl acetate (151 mL), acetonitrile (30.2 mL) and methanol (38 mL), and (-)-di-paratoluoyl-L-tartaric acid (2.70 g, 6.98 mmol) was added and stirred at room temperature for 3 days to obtain a solid. The solid obtained was filtered and then washed with a mixed solution of isopropyl acetate and acetonitrile (9 / 1). The mother liquor obtained was concentrated to 10 times its volume, and isopropyl acetate (10 times its volume), 5N aqueous sodium hydroxide solution (4.65 ml, 23.269 mmol) and water (4 times its volume) were added. The aqueous layer was removed and then washed with water (4 times its volume). After concentrating to 5 times its volume, isopropyl acetate (10 times its volume) was added to the mixture to azeotrope to 5 times its volume. (+)-di-paratoluoyl-D-tartaric acid (3.15 g, 8.144 mmol) was added to a solution of (+)-dipivaloyl-D-tartaric acid (1.852 g, 5.817 mmol) in methanol (38 mL), acetonitrile (30.2 mL) and isopropyl acetate (151 mL), and the mixture was stirred at room temperature overnight. (+)-Di-paratoluoyl-D-tartaric acid (0.05 equivalents) and isopropyl acetate (10 times the amount) were added. The entire amount was recovered by concentration, neutralization with sodium hydroxide, and washing with pure water. (+)-Di-paratoluoyl-D-tartaric acid (3.15 g, 8.144 mmol) was added to a solution of (+)-dipivaloyl-D-tartaric acid (0.2 equivalents) in isopropyl acetate (151 mL), acetonitrile (30.2 mL), and methanol (38 mL), and the mixture was stirred overnight at room temperature. (+)-Di-paratoluoyl-D-tartaric acid (0.05 equivalents) was added to the reaction mixture, and the mixture was stirred at room temperature for 4 hours. (+)-Di-paratoluoyl-D-tartaric acid (0.025 equivalents) and isopropyl acetate (10 times the amount) were added to the reaction mixture, and the mixture was stirred overnight at room temperature. The entire amount was recovered by concentration, neutralization with sodium hydroxide, and washing with pure water. (+)-Di-paratoluoyl-D-tartaric acid (3.15 g, 8.14 mmol) was added to a solution of (+)-dipivaloyl-D-tartaric acid (0.2 equivalents) in isopropyl acetate (151 mL), acetonitrile (30.2 mL) and methanol (38 mL), and the mixture was stirred overnight at room temperature. Isopropyl acetate (10 times the amount) was added. After 7 hours, the resulting solid was filtered and washed with isopropyl acetate to obtain the title compound (3.45 g). (Analysis conditions) Chromatography using Daicel CHIRALPAK (registered trademark) IA (0.46 cm x 25 cm) (mobile phase: ethanol: n-hexane (20:80), 40°C, flow rate: 1.0 mL / min, detection: UV (254 nm)) (Analysis results) The retention time of the title compound was 8.52 minutes, and the optical purity was 99.2% ee.
[0059] (2) Synthesis of tert-butyl (1R,3s,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate 2,5-Dichloropyrimidine (288 mg, 1.93 mmol), tert-butyl (1R,3s,5S)-3-((3S,4R)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate hemi(2S,3S)-2,3-bis((4-methylbenzoyl)oxy)succinate (500 mg, 0.966 mmol) and potassium carbonate (267 mg, 1.93 mmol) in N,N-dimethylformamide (10 mL) were stirred at 80° C. for 24 hours. After cooling to room temperature, water was added and the mixture was extracted three times with ethyl acetate. The organic layer was collected and concentrated. The resulting residue was purified by column chromatography (silica gel, 10-100% ethyl acetate / n-heptane) to obtain the title compound (368 mg). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.24-1.27(m,2H),1.41-1.49(m,2H),1.46(s,9H),1.61(brs,4H),1.82-1.98(m,4H),2.68(d,J=14.04Hz,1H),2.75(td,J= 12.91,3.17Hz,1H),3.30(s,3H),3.36(brs,1H),4.11-4.32(m,2H),4.68-4.80(m,1H),5.12(dt,J=14.27,2.61Hz,1H),8.16(s,2H).
[0060] (3) Synthesis of tert-butyl (1R,3s,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-hydroxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate A mixture of tert-butyl (1R,3s,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (300 mg, 0.687 mmol) and 48% hydrobromic acid (5 mL) was stirred at room temperature for 20 minutes, then heated at 100 ° C. for 2.5 hours. After stirring at room temperature overnight, the resulting reaction mixture was concentrated under reduced pressure. Tetrahydrofuran (10 mL) and a saturated aqueous solution of sodium bicarbonate were added to the resulting residue, and di-tert-butyl dicarbonate (165 mg, 0.755 mmol) was added thereto at room temperature. After confirming the completion of the reaction by UPLC, ethyl acetate and water were added to separate the organic layer. The aqueous layer was extracted again with ethyl acetate, combined with the organic layer obtained earlier, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was washed with a mixed solvent of 10% ethyl acetate / n-heptane to obtain the title compound (226 mg). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):1.28-1.34(m,2H),1.46(s,9H),1.59-1.72(m,6H),1.75-1.97(m,4H),2.70-2.83(m,1H),2.91(dd,J=14.04,0.9 1Hz,1H),3.97-4.03(m,1H),4.09-4.34(m,2H),4.68-4.79(m,1H),4.81-4.91(m,1H),8.18(s,2H).MS(ESI)m / z:423[M+H] +
[0061] (4) Synthesis of tert-butyl (1R,3s,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl (1R,3s,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-hydroxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (50 mg, 0.118 mmol) in N,N-dimethylformamide (1 mL), sodium hydride (60%, dispersed in liquid paraffin, 7.09 mg, 0.177 mmol) was added under ice cooling. After stirring for 30 minutes, ethyl iodide (0.019 mL, 0.236 mmol) was added and stirred at room temperature for 16 hours. After adding water and ethyl acetate to the reaction solution, the organic layer was separated and concentrated. The resulting residue was purified by column chromatography (silica gel, 1-20% ethyl acetate / n-heptane) to obtain the title compound (42.5 mg). MS(ESI)m / z:451[M+H] +
[0062] (5) Synthesis of (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide tert-Butyl (1R,3s,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (42.5 mg, 0.094 mmol) was treated with trifluoroacetic acid (1 mL) for 30 minutes and then concentrated. The resulting residue was dissolved in methanol and applied to a Waters Porapak Rxn® CX (0.4 g). After washing the solid phase with methanol (6 mL), the product was eluted with ammonia (2 mol / L methanol solution, 6 mL), and the eluate was concentrated under reduced pressure. A mixture of the obtained residue, (S)-2-bromo-2-cyclopropylacetamide (51.6 mg, 0.188 mmol) obtained by the same operation as in Production Example 5, potassium carbonate (26.0 mg, 0.188 mmol) and acetonitrile (2 mL) was stirred at room temperature for 17 days. The reaction mixture was filtered using acetonitrile (3 mL), and the obtained filtrate was separated in 500 μL portions per run using supercritical fluid chromatography (mobile phase CO2:methanol (75:25), 120 bar, 40 °C, flow rate: 100 mL / min) using Daicel CHIRALPAK (registered trademark) IA / SFC (3 cm x 25 cm), to obtain the title compound (22.2 mg) with a retention time of 7.55 minutes. 1 H-NMR (400MHz, CDCl 3 )δ(ppm):0.26-0.38(m,1H),0.40-0.58(m,2H),0.59-0.68(m,1H),0.71-0.83(m,1H ),0.98-1.92(m,12H),1.04(t,J=7.02Hz,3H),2.07(brd,J=9.06Hz,1H),2.61-2.81( m,2H),3.13-3.30(m,2H),3.45(brs,1H),3.61-3.75(m,1H),3.84-3.92(m,1H),4.66 -4.76(m,1H),4.93-5.11(m,1H),5.17-5.32(m,1H),6.90-7.03(m,1H),8.16(s,2H). MS(ESI)m / z:448[M+H] + (Analysis conditions) Supercritical fluid chromatography using Daicel CHIRALPAK (registered trademark) IA-3 (0.46 cm x 25 cm) (mobile phase CO2:methanol (80:20), 40°C, flow rate: 1.2 mL / min, detection: UV (257 nm)) (Analysis results) The retention time of the title compound was 2.19 minutes, and the optical purity was >99.9% ee.
[0063] Preparation of single crystals of (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide and X-ray crystal structure analysis The title compound (1.37 mg) obtained in Example 3 was dissolved in acetonitrile (600 μL). 200 μL of the solution was placed in a vial and the cap was closed loosely (solvent evaporation method). One day later, a single crystal of the title compound (a dimer crystal with two molecules of acetonitrile added) was obtained in the vial. X-ray crystal structure analysis was performed on the obtained single crystal under the following conditions. The X-ray crystal structure of the title compound is shown in FIG. 2. Analytical equipment: XtaLAB PROP200 MM007HF (Rigaku, Japan) Software: CrysAlisPro (Rigaku Oxford Diffraction) X-ray: multi-layer mirror monochromated Cu-Kα (40kV / 30 mA) Measurement method: ω axis oscillation method Camera length: 35 mm Measurement temperature: -170℃
[0064] Example 4 Synthesis of (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide [ka]
[0065] (1) Synthesis of ethyl (1R,3s,5S)-3-((S)-2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate To a 13 mm screw-cap test tube was added ethyl (1R,3s,5S)-3-(tosyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate (CAS No. 2236076-85-8) (200 mg, 0.566 mmol), nickel(II) bromide ethylene glycol dimethyl ether complex (17.5 mg, 0.057 mmol), 4,4-di-tert-butyl-2,2-dipyridyl (15.2 mg, 0.057 mmol), potassium iodide (94.0 mg, 0.566 mmol), and manganese (62.2 mg, 1.13 mmol). Then, a solution of tert-butyl (S)-2-methyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)-carboxylate (CAS No. 876922-74-6) (195 mg, 0.566 mmol) in N,N-dimethylacetamide (4.0 mL) and 4-ethylpyridine (0.064 mL, 0.566 mmol) were added under a nitrogen stream. The resulting mixture was stirred at 80° C. for 12.5 hours under a nitrogen atmosphere. After cooling to room temperature, it was diluted with ethyl acetate. Insoluble matter was removed by cotton plug filtration, and the eluate was partitioned with water and ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate. The organic layers were combined, washed three times with water, and concentrated under reduced pressure to obtain the coupling reaction product as a crude product. Trifluoroacetic acid (1.0 mL) was added to a solution of the obtained crude product in dichloromethane (4.0 mL) and stirred at room temperature for 1 hour. The solvent was removed by blowing nitrogen into the reaction mixture, and the residue was diluted with methanol. The obtained methanol solution was applied to a Waters PоraPak Rxn (registered trademark) CX (20 cc (2 g) cartridge). The solid phase was washed with methanol (20.0 mL) and then eluted with ammonia (2N methanol solution, 20 mL). The eluate was concentrated under reduced pressure to obtain the crude product of the title compound (120 mg). MS(ESI)m / z:279[M+H] +
[0066] (2) Synthesis of ethyl (1R,3s,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate A mixture of ethyl (1R,3s,5S)-3-((S)-2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (120 mg, 0.431 mmol), 10% palladium carbon (N.E. Chemcat Corporation, 48.47% water content, 183 mg, 0.083 mmol) and methanol (4.0 mL) was stirred under a hydrogen atmosphere for 6.5 hours. Insoluble matter was removed by filtration through Celite®, and the mixture was concentrated under reduced pressure to obtain the reduced product (113 mg) as a mixture of cis and trans isomers. MS(ESI)m / z:281[M+H] + A mixture of the obtained reductant (113 mg), 2-chloro-5-fluoropyrimidine (0.048 mL, 0.517 mmol), cesium carbonate (281 mg, 0.862 mmol) and N,N-dimethylacetamide (2.0 mL) was stirred for 8 hours at 100° C. The mixture was purified by column chromatography (silica gel, 0-30% ethyl acetate / n-heptane) to obtain the title compound (82.0 mg) as a cis-trans mixture. MS(ESI)m / z:377[M+H] + (Analysis conditions) Supercritical fluid chromatography using Daicel CHIRALPAK (registered trademark) IF-3 (3.0 mm x 50 mm) (mobile phase CO2:methanol (70:30), 40°C, flow rate: 1.2 mL / min, detection: UV (210-400 nm)) (Analysis results) The retention time of the title compound was 1.02 minutes, and the retention time of the trans isomer was 1.23 minutes. The cis:trans ratio was 4:5 (peak area ratio), and the optical purity was >99% ee. The resulting cis-trans mixture was separated into 10 mg portions per run using a Daicel CHIRALPAK (registered trademark) IF / SFC (3 cm x 25 cm) column (mobile phase: CO2:methanol (70:30), 120 bar, 40°C, flow rate: 100 mL / min) to obtain the title compound (34.0 mg) which eluted first with a retention time of 5.55 min. 1 H-NMR (400MHz, CDCl3 )δ(ppm):1.17(d,J=6.34Hz,3H),1.23(t,J=7.25Hz,3H),1.19-2.02(m,14H),3.09(ddd,J=13.70,10.9 9,5.66Hz,1H),4.10(q,J=7.10Hz,2H),4.17-4.30(m,3H),4.34(dd,J=13.59,7.25Hz,1H),8.13(s,2H). MS(ESI)m / z:377[M+H] + (Analysis conditions) Supercritical fluid chromatography using Daicel CHIRALPAK (registered trademark) IF-3 (3.0 mm x 50 mm) (mobile phase CO2:methanol (70:30), 40°C, flow rate: 1.2 mL / min, detection: UV (245 nm)) (Analysis results) The retention time of the title compound was 1.02 minutes, the cis:trans ratio was >99:1, and the optical purity was >99% ee.
[0067] (3) Synthesis of (1R,3s,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octane A mixture of ethyl (1R,3s,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (34 mg, 0.09 mmol) and 48% hydrobromic acid (2.0 mL) was stirred at 100° C. for 1 hour. The reaction mixture was neutralized by adding 5N aqueous sodium hydroxide solution at 0° C. The mixture was extracted three times with dichloromethane, and the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain the title compound (21.7 mg). MS(ESI)m / z:305[M+H] +
[0068] (4) Synthesis of (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide A mixture of (1R,3s,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octane (5.00 mg, 0.016 mmol), potassium carbonate (4.54 mg, 0.033 mmol), (S)-2-bromo-2-cyclopropylacetamide (8.24 mg, 0.033 mmol) and acetonitrile (1.0 mL) was stirred at room temperature for 7 days. Potassium carbonate (4.54 mg, 0.033 mmol) and (S)-2-bromo-2-cyclopropylacetamide (8.24 mg, 0.033 mmol) were added to the reaction mixture, and the mixture was further stirred at room temperature for 3 days. An aqueous solution of ammonium chloride was added to the reaction mixture to stop the reaction. The mixture was extracted with ethyl acetate, and the organic layer was washed with water and concentrated under reduced pressure to obtain a crude product. The obtained crude product was diluted with methanol and applied to a Waters PoraPak Rxn (registered trademark) CX (6 cc (400 mg) cartridge). The solid phase was washed with methanol (6.0 mL) and then eluted with ammonia (2N methanol solution, 6 mL). The eluate was concentrated under reduced pressure, and the obtained residue was purified by thin layer chromatography (NH, dichloromethane) to obtain the title compound (3.74 mg). 1 H-NMR (400MHz, CDCl 3 )δ(ppm):0.25-0.36(m,1H),0.39-0.51(m,1H),0.51-0.59(m,1H),0.59-0.70(m,1H),0.70 -0.84(m,1H),1.18(d,J=6.34Hz,3H),1.21-1.55(m,9H),1.61-1.95(m,5H),2.04(d,J=9.06 Hz,1H),3.10(ddd,J=13.70,10.99,5.21Hz,1H),3.15-3.28(m,1H),3.80-3.94(m,1H),4.1 7-4.29(m,1H),4.35(dd,J=13.59,7.25Hz,1H),5.18(brs,1H),6.94(brs,1H),8.14(s,2H). MS(ESI)m / z:402[M+H] +
[0069] Preparation and X-ray crystal structure analysis of single crystals of (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide The title compound (0.81 mg) obtained in Example 4 was dissolved in methanol (600 μL). A vial containing 200 μL of the solution was slowly placed in a vial slightly larger than the vial and containing 2 mL of tert-butyl methyl ether, and the cap was closed (vapor diffusion method). After 12 days, a single crystal of the title compound was obtained in the vial. X-ray crystal structure analysis was performed on the obtained single crystal under the following conditions. The X-ray crystal structure of the title compound is shown in FIG. 3. Analytical equipment: XtaLAB PROP200 MM007HF (Rigaku, Japan) Software: CrysAlisPro (Rigaku Oxford Diffraction) X-ray: multi-layer mirror monochromated Cu-Kα (40kV / 30 mA) Measurement method: ω axis oscillation method Camera length: 35 mm Measurement temperature: -170℃
[0070] Pharmacological test examples The following pharmacological tests were carried out using the compounds of Examples 1 to 4.
[0071] Test Example 1-1 Evaluation of agonist activity against OX1R and OX2R Human Embryonic Kidney cells 293 (HEK293) cells expressing hOX1R and hOX2R were seeded at 10,000 cells per well of a 384-well microplate (Greiner) and cultured for 24 hours in high-glucose DMEM (Fujifilm Wako Pure Chemical) supplemented with 10% FBS (Thermo Scientific) and 1% Penicillin-Streptomycin (Fujifilm Wako Pure Chemical). After removing the medium, 40 μL of assay buffer (20 mM HEPES (Sigma-Aldrich), Hank's balanced salt solution (Gibco), 0.1% BSA (Sigma-Aldrich), 0.1% Pluronic F-127 (Biotium, Inc.)) containing Calcium 4 dye (Molecular Device Corporation) and 2.5 mM probenecid (Sigma-Aldrich) was added and incubated for 60 minutes. After further adding 20 μL of assay buffer, 20 μL of assay buffer containing a test compound was added to start the reaction. The change in intracellular calcium ion concentration due to the reaction was measured by measuring the fluorescence intensity ratio by dual wavelength excitation at 480 nm and 540 nm as a fluorescence value using FDSS7000 (Hamamatsu Photonics). The test compound was dissolved in DMSO to make it 10 mM, and the final concentration was 3×10 -10 M to 1x10 -7 The compound was diluted with the assay buffer to a final concentration of 0.1% (DMSO final concentration: 0.1%). The fluorescence value of the wells to which the compound-free buffer was added was 0%, and that of the wells to which the compound was added was OX-A (Peptide Institute). The fluorescence value of the well to which 10 nM was added was set as 100%, and the 50% agonistic concentration (EC50 value) was calculated from the fluorescence value when various concentrations of the test compound were added. The agonistic activity value of each compound is shown in Table 1.
[0072] [Table 1]
[0073] Test Example 1-2 Evaluation of agonist activity against OX1R and OX2R Human Embryonic Kidney cells 293 (HEK293) cells expressing hOX1R and hOX2R were seeded at 10,000 cells per well of a 384-well microplate (Greiner) and cultured for 1 day in high glucose DMEM (Fujifilm Wako Pure Chemical) supplemented with 10% FBS (Thermo Scientific) and 1% Penicillin-Streptomycin (Fujifilm Wako Pure Chemical). After removing the medium, 30 μL of assay buffer (20 mM HEPES (Sigma-Aldrich), Hank's balanced salt solution (Gibco), 0.1% BSA (Sigma-Aldrich), 0.1% Pluronic F-127 (Biotium, Inc.)) containing Calcium 4 dye (Molecular Device Corporation) and 2.5 mM probenecid (Sigma-Aldrich) was added and incubated for 60 minutes. 30 μL of assay buffer containing the test compound was added to initiate the reaction. The change in intracellular calcium ion concentration due to the reaction was measured by measuring the fluorescence intensity ratio by dual wavelength excitation at 480 nm and 540 nm using FDSS7000 (Hamamatsu Photonics). The test compound was dissolved in DMSO to a concentration of 10 mM, and the final concentration was 3 x 10 -11 M to 1x10 -5 The wells were diluted with assay buffer to give a final concentration of 10 nM (final DMSO concentration was 0.1%). The fluorescence value of the wells to which a buffer containing no compound was added was set at 0%, and the fluorescence value of the wells to which 10 nM OX-A (Peptide Institute) was added was set at 100%, and the 50% agonistic concentration (EC50 value) was calculated from the fluorescence value when various concentrations of the test compound were added. The agonistic activity values of each compound are shown in Table 2.
[0074] [Table 2]
[0075] Test Example 2 Increase in spontaneous locomotor activity Increased locomotion in mice is one of the indicators of the stimulant effect, along with increased wakefulness time, elevated body temperature, and enhanced cardiovascular parameters. In this test example, the stimulant effect was evaluated by measuring the spontaneous locomotor activity of mice. Male C57BL / 6NCrl mice (18-19 weeks old, Charles River Japan, 4 mice per group) were used in the experiment. Spontaneous locomotor activity was measured by irradiating infrared rays from the side of the measurement cage using a locomotion measuring device (VersaMax open field, AccuScan Instruments, Inc.) and quantifying the number of times the mouse passed through the irradiated light. The mice were placed in the measurement cage and allowed to acclimate for 3 hours, after which the compound was orally administered (10 mg / kg). Spontaneous locomotor activity was measured for 2 hours after administration. For the test compound administration group, a solution of the test compound dissolved in 0.1 mol / L hydrochloric acid containing 5% (v / v) DMSO and 5% (v / v) Kolliphor (registered trademark) EL was administered to the mice. In the control group, only the above-mentioned solvent containing no test compound was administered to mice.
[0076] The results are shown in Table 3. The amount of spontaneous locomotor activity is expressed as a percentage of the amount of spontaneous locomotor activity in the test compound administration group, assuming that the amount of spontaneous locomotor activity in the control group is 100%.
[0077] [Table 3]
[0078] As is clear from Table 3, the compounds of the present invention enhanced the spontaneous locomotor activity of mice, which indicates that the compounds of the present invention have a stimulating effect.
[0079] Test Example 3: Awakening effect of the compound of the present invention when orally administered to wild-type mice during the dark period The experimental animals used were wild type (WT) male mice of the C57BL / 6 strain. Under isoflurane anesthesia, 13-week-old mice underwent surgery to implant electrodes for measuring electroencephalograms and electromyograms. After the surgery, the mice were acclimated to the lighting cycle and experimental procedures, and then electroencephalograms and electromyograms were measured. Mice in which electroencephalograms and electromyograms could be normally recorded were used for the experiment. A solvent (0 mg / kg) or a solution in which the compound of Example 1 was dissolved in a solvent (1, 3 or 10 mg / kg) was orally administered 30 to 15 minutes before lights-off. The solvent used was a 0.1 mol / L hydrochloric acid solution containing 5% (v / v) DMSO and 5% (v / v) Kolliphor (registered trademark) EL. Electroencephalograms and electromyograms were recorded for about 24 hours from 1 hour before lights-off. Mice were repeatedly used with a washout period of 2 days or more. The obtained electroencephalogram and electromyogram data of each mouse were used to determine the sleep stage for each epoch (10 seconds) using sleep analysis software (SleepSign; Kissei Comtec Co., Ltd.). The time (sleep latency) until the first sleep (sleep of 8 epochs or more starting from non-REM sleep) appeared after lights-out was measured for each mouse. The number of mice in each administration group was 16, and comparison of sleep latency between the solvent administration group (control group) and the compound administration group of Example 1 was performed by Dunnett's multiple comparison test after survival time analysis considering the correspondence of the same individual with the experimental time, and the significance level for both was set at 5% on both sides.
[0080] The sleep latency of mice administered with the solvent and 1, 3 and 10 mg / kg of the compound of Example 1 was 0.23 hours, 0.28 hours, 0.44 hours and 2.07 hours, respectively. In addition, the sleep latency of the group administered with 3 or 10 mg / kg of the compound of Example 1 was significantly increased compared to the group administered with the solvent. That is, when the compound of Example 1 was orally administered during the light period (ZT12), which is the beginning of the active period for mice, a dose-dependent extension of the sleep latency was confirmed.
[0081] Test Example 4: Awakening effect and cataplexy-like behavior suppression effect of the compound of the present invention when orally administered to orexin-deficient mice (orexin / ataxin 3 mice) during the dark period The experimental animals used were orexin / ataxin-3 mice (orexin / ataxin-3 Tg / + (hereinafter referred to as "Tg mice"), Hara et al., Neuron, 30, 345-54, 2001) with a genetic background of C57BL / 6 strain, and wild-type mice (hereinafter referred to as "WT mice") of the same litter as controls. Electroencephalogram and EMG measurement electrodes were implanted in 12-week-old (±2-week-old) mice under isoflurane anesthesia. After the surgery, the mice were acclimated to the lighting cycle and experimental procedures, and then electroencephalogram and EMG measurements were performed. Mice that could normally record electroencephalogram and EMG were used in the experiment. A solvent (0 mg / kg) or a sample (a solution of the compound of Example 1 dissolved in the solvent; 0.3, 1, or 3 mg / kg) was orally administered 30 to 15 minutes before lights-off. The solvent used was a 0.1 mol / L hydrochloric acid solution containing 5% (v / v) DMSO and 5% (v / v) Kolliphor (registered trademark) EL. Electroencephalograms and electromyograms were recorded for about 24 hours from 1 hour before lights-out. Mice were repeatedly used with a washout period of 2 days or more. The obtained electroencephalogram and electromyogram data of each mouse were used to determine the sleep stage every epoch (10 seconds) for up to 4 hours using sleep analysis software (SleepSign; Kissei Comtec Co., Ltd.). In this experiment, cataplexy-like symptoms refer to the phenomenon in which REM sleep appears immediately after a wakeful state of 4 or more consecutive epochs (direct transitions from wake to REM sleep (DREM)). DREM in mice is an analog of cataplexy in humans (Exp Neurol. 2009;217:46-54). For each animal, the time until the first sleep (sleep of 8 or more consecutive epochs excluding DREM) appeared after lights out (sleep latency) and the time until the first DREM appeared (DREM latency) were measured. The number of animals was 8 for the solvent administration group and 14 for the compound administration group of Example 1. Comparison of sleep latency between the pathological control group and the compound administration group was performed by Dunnett's multiple comparison test after survival time analysis considering the correspondence between the experimental times and the same individuals, and the significance level for both was set at 5% on both sides. Comparison of DREM latency between the normal control group and the pathological control group was performed by survival time analysis considering the correspondence between the experimental times and the same individuals.When the above test was significant, a comparison between the pathological control group and the group administered the compound of Example 1 was performed using a Dunnett's multiple comparison test after survival time analysis taking into account the correspondence of the same individuals to the experimental times, with the significance level set at 5% on both sides.
[0082] The sleep latency of the Tg mice administered with the vehicle and 0.3, 1 and 3 mg / kg of the compound of Example 1 was 0.21 hours, 0.31 hours, 0.64 hours and 2.42 hours, respectively, and the sleep latency was significantly increased in the groups administered with 1 and 3 mg / kg of the compound of Example 1. That is, when the compound of Example 1 was orally administered during the light period (ZT12), which is the beginning of the active period for mice, the sleep latency was extended in a dose-dependent manner from 1 mg / kg in the orexin-deficient mice.
[0083] The DREM latency in WT mice administered with the vehicle was 4.00 hours. On the other hand, the DREM latency in Tg mice administered with the vehicle and 0.3, 1 and 3 mg / kg of the compound of Example 1 was 1.16 hours, 1.50 hours, 2.26 hours and 4.00 hours, respectively, and a significant and dose-dependent increase in DREM latency was confirmed in the groups administered with 0.3, 1 and 3 mg / kg of the compound of Example 1 compared to the group administered with the vehicle. In other words, the cataplexy-like symptoms (DREM) exhibited by orexin-deficient mice were dose-dependently suppressed by administration of the compound of the present invention.
Claims
1. The following formula (I) [Case 1] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [Case 2] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III): [C3] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV): [C4] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula A medicine comprising a compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
2. The following formula (I) [C5] or a pharma- ceutical acceptable salt thereof.
3. The following formula (II) [C6] or a pharma- ceutical agent comprising a medicament comprising a medicament for treating a pulmonary arthritis.
4. The following formula (III): [C7] or a pharma- ceutical agent comprising a medicament comprising a medicament for treating a pulmonary arthritis.
5. The following formula (IV): [C8] or a pharma- ceutical agent comprising a medicament comprising a medicament for treating a pulmonary edema, comprising: (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula:
6. The following formula (I) [C9] (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the formula The following formula (II) [C10] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide represented by the formula The following formula (III): [C11] (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide represented by the formula and The following formula (IV): [C12] (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the formula A pharmaceutical composition comprising a compound selected from the group consisting of:
7. The pharmaceutical agent according to any one of claims 1 to 5, which is an orexin type 2 receptor agonist.
8. The pharmaceutical agent according to any one of claims 1 to 5, which is a therapeutic agent for narcolepsy.
9. The pharmaceutical agent according to any one of claims 1 to 5, which is a therapeutic agent for cataplexy.
Citation Information
Patent Citations
New ligand of neuropeptide receptor hfgan72
JP1998229887A
New g-protein binding receptor(Hfgan72x)
JP1998327888A
New g-protein binding receptor(Hfgan72y)
JP1998327889A
Cdna clone my1 encoding new human 7-trans membrane receptor
JP1999178588A
Novel diazabicyclic aryl derivatives and their pharmaceutical uses
JP2008517032A
